Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 History  





2 Products  





3 Awards  





4 References  





5 External links  














Pacific Edge Limited







Add links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Pacific Edge Limited
Company typePublic

Traded as

NZX: PEB
IndustryCancer diagnostics
Founded2001
Headquarters
Dunedin, New Zealand and Hershey, USA

Area served

New Zealand, Australia, Spain, United States of America

Key people

David Darling[1][2] (Group CEO) and Jackie Walker (CEO of Pacific Edge Diagnostics USA)
ProductsCxBladder Suite of bladder cancer diagnostics tools
ServicesUrology
Revenue$4m as at November 2015

Number of employees

Approx 50 globally
Websitepacificedgedx.com

Pacific Edge Limited, based in New Zealand, focuses on cancer diagnostics with a suite of bladder cancer diagnostic tools using genetic biomarkers. The company operates with a head office in Dunedin, New Zealand, and also has an office in Hershey, USA. It is listed on the New Zealand NZX main board stock exchange and is included in the NZX 50 Index.[3]

History[edit]

Pacific Edge, founded in August 2001,[4] utilizes genetic biomarkersinurine for cancer detection. Their approach is positioned as cost-effective compared to other diagnostic methods.[5] The company offers diagnostic services in New Zealand and the United States and has partnerships in Europe and Australia.

Listed on the New Zealand NZX index, Pacific Edge has undertaken capital raising initiatives, with rounds in 2013 and 2015 aimed at advancing the commercialization of their diagnostic tests in the United States.[6] In June 2020, Pacific Edge secured a commercial relationship with Kaiser Permanente, one of the largest health insurance providers in the U.S., for its bladder cancer tests.[7]

Products[edit]

Pacific Edge offers a series of bladder cancer diagnostic tests known as CxBladder. These tests include specialist subtype products designed for the detection of cancerous cells and to aid clinicians and oncologistsintriage.[8] The tests are based on non-invasive urine samples, utilizing RNA and protein assays. CxBladder is noted for its sensitivity and potential for earlier detection of bladder cancer, compared to other diagnostic methods such as cytology.[9][10][11][12][13][14]

Awards[edit]

Pacific Edge has won a number of awards, including:

References[edit]

  1. ^ "PEB.NZ Profile - Pacific Edge Limited Ordinary S Stock - Yahoo! Finance". Yahoo! Finance. Retrieved 31 December 2015.
  • ^ "Pacific Edge first-half loss widens". The New Zealand Herald. Retrieved 31 December 2015.
  • ^ "Pacific Edge Limited". Retrieved 31 December 2015.
  • ^ "NZX Main Board - PEB Analysis". NZX. Retrieved 31 December 2015. Pacific Edge Limited (PEB) was formed in August 2001 following acquisition of intellectual property from the University of Otago.
  • ^ "Pacific Edge shares soar to new high". New Zealand Herald. 22 October 2013. ISSN 1170-0777. Retrieved 31 December 2015.
  • ^ "Pacific Edge seeks $35.3M to fund US growth". The New Zealand Herald. Retrieved 31 December 2015.
  • ^ "Kaiser Permanente Approves Commercial Use of Cxbladder - NZX, New Zealand's Exchange". www.nzx.com. Retrieved 25 June 2020.
  • ^ "Suite of cancer products grows". Otago Daily Times. 29 December 2015. Retrieved 31 December 2015.
  • ^ Alan Wood (27 May 2015). "Pacific Edge's FY loss widens to $10.58m, plans to raise $35.3m". Stuff.co.nz. Retrieved 31 December 2015.
  • ^ Janis C. Kelly (26 October 2015). "Urinary Biomarkers Not Useful for Bladder Cancer Diagnosis". Medscape. Retrieved 31 December 2015.
  • ^ MARTA STEEMAN (9 June 2015). "Singapore hospital to trial Pacific Edge's main bladder cancer detection product". Stuff.co.nz. Retrieved 31 December 2015.
  • ^ "Warning over bladder cancer test". Stuff.co.nz. 11 July 2014. Retrieved 31 December 2015.
  • ^ "Pacific Edge sales up; still no profit". Otago Daily Times. 27 November 2015. Retrieved 31 December 2015.
  • ^ "Pacific Edge gets US approval for Dunedin laboratory". The New Zealand Herald. Retrieved 31 December 2015.
  • External links[edit]



    Retrieved from "https://en.wikipedia.org/w/index.php?title=Pacific_Edge_Limited&oldid=1210513814"

    Categories: 
    Urology organizations
    New Zealand brands
    Companies listed on the New Zealand Exchange
    Companies in the S&P/NZX 50 Index
    Companies based in Dunedin
    Companies established in 2001
    Medical technology companies of New Zealand
    New Zealand companies established in 2001
    Hidden categories: 
    Use dmy dates from April 2022
    Use New Zealand English from February 2024
    All Wikipedia articles written in New Zealand English
    Articles needing additional references from December 2015
    All articles needing additional references
     



    This page was last edited on 27 February 2024, at 00:35 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki